Classifications

• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N25/00—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests
  • A01N25/02—Biocides, pest repellants or attractants, or plant growth regulators, characterised by their forms, or by their non-active ingredients or by their methods of application, e.g. seed treatment or sequential application; Substances for reducing the noxious effect of the active ingredients to organisms other than pests containing liquids as carriers, diluents or solvents

Definitions

• This invention relates in general to a composition for controlling ectoparasites. More particularly this invention relates to such a composition employing a pyrethroid in concentrations greater than 50% w/w.
• Ectoparasites such as ticks and fleas are often found on domesticated animals, such as dogs. Ectoparasites will feed off their animal host and are a constant source of irritation to the animal. It is therefore desirable to control such infestations. By control, it is meant that, desirably, all parasites on the host are killed. Control of tick infestation on all mammals, especially household pets, has recently assumed greater importance than at any other recent time because of the discovery that certain tick species may carry the micro-organism responsible for the transmission of Lyme disease to humans.
• compositions and methods for controlling ectoparasites are systemic products. That is, they are products containing active parasiticides that enter the bloodstream of the animal in order to create the insecticidal effect.
• Systemic insecticides are generally less desirable if suitable alternatives exist. They have shown some efficacy against fleas, but have generally not been useful in controlling ticks. Because systemic products, even if topically applied, must enter into the host bloodstream, they are more likely to be toxic to the host. In addition, systemic products that are not applied topically can be difficult to administer. They may require injection equipment or involve the difficult task of getting an animal to swallow oral formulations.
• GB-A-2088212 discloses liquid compositions containing up to about 50% w/w of a pyrethroid, and methods for their topical application. More specifically, GB-A-2088212 discloses the dissolution of solid pyrethroids into liquid formulations by using undesirable, irritating, organic solvents such as xylene, toluene and cyclohexanone, optionally in conjunction with alkyl glycol ethers.
• a novel parasiticidal composition according to the invention for topical administration to non-human domesticated animals, comprises 65 to 85% by weight of permethrin, and alkyl glycol ether carrier.
• the weak solvent power of the glycols could be compatible with commercial production methods.
• the active ingredients according to the present invention are formulated in an alkyl glycol ether solvent, the resulting liquid formulation can then be used as an ingredient in formulating other topical compositions.
• Concentrations of more than 50% w/w make topical application of the composition more convenient than ever before. The higher the concentration, the smaller the dose for effective ectoparasite control. Such small doses can be applied without the treated animal being made aware thus easing administration. Formulations containing more than 50% w/w of a pyrethroid thus obtain many advantages not taught by the prior art of using formulations with maximum concentrations of up to 50% w/w.
• Topical compositions can be formulated to take a variety of physical states. They can be a mixture of liquids or a solid active agent can be dissolved in solution. Alternatively, the active agent may be carried in a suspension or emulsion.
• the suspensions can be water or oil based sols, gels, or ointments.
• Emulsion carriers contain both aqueous and oily components and can take the form of creams, lotions, or ointments.
• an optimal composition has the following characteristics.
• the composition comprises more than 50% w/w of the active agent so that the smallest effective dose may be achieved.
• the carrier components of the formulation facilitate delivery, adsorption on the hair and distribution of the active agent to the parasite.
• the carrier may inhibit absorption of the active agent into the host and thus avoid systemic toxicity.
• the carrier may also comprise ingredients that soothe or prevent irritation as well as merely employing solvents that are non-irritating.
• the choice of carrier can also be varied to optimize frequency of dosing according to particular environmental conditions. For example, oily carriers resist washing.
• Formulations comprised of oily carriers reduce dosing frequency for hosts exposed to rain and water.
• Formulations comprised of aqueous carriers are more suited to dry environs. If the host is in dry environs the aqueous formulation is less likely to be washed off and the required frequency of dosing remains low.
• Formulations with pyrethroid concentrations in excess of 50% w/w can be packaged in a single dose package.
• a single 1 cc dose of a liquid formulation comprised of 65% w/w permethrin and 35% w/w 2-(2-methoxyethoxy)ethanol can be packaged in a collapsible 1 cc tube. Because, the formulation avoids the use of strong organic solvents like xylene, cyclohexanone, and toluene, there is greater choice of tube material.
• Single dose containers make storage and disposal more convenient for animal owners.
• Multiple dose liquid formulations can be packaged in photoresistant containers of more than 1 cc capacity.
• the high concentration composition also decreases container size requirements for multiple dose containers as well as the container size requirements for single dose containers for larger animals. Again, the smaller container sizes are more conveniently stored and disposed.
• compositions including a pyrethroid in concentrations greater than 50% w/w and up to 85% w/w can be prepared and that said highly concentrated composition is effective for topical application for control of ectoparasites such as fleas and ticks, on animals, especially canines, while remaining non-toxic and non-irritating to the host.
• the pyrethroid used is permethrin.
• the composition preferably comprises 65% w/w permethrin in a carrier, preferably the solvent carrier 2-(2-methoxyethoxy)ethanol.
• the composition may include other inert ingredients such as perfumes, skin conditioners or coat sheeners.
• a preferred composition is in a pourable form so that it can be easily applied to the fur and skin of host animals.
• the preferred composition is non-irritating to the host skin, coat and fur and is also not systemically toxic to the host.
• Pyrethroids have shown efficacy against ectoparasites. Suitable pyrethroids include permethrin, phenothrin, cypermethrin, cyhalothrin, deltamethrin, flumethrin, cyfluthrin, cyphenothrin, tralomethrin, tralocythrin and fenvalerate.
• the most preferred pyrethroid for use in this invention is permethrin, i.e. 3-(phenoxyphenyl)methyl (1 RS )- cis , trans -3-(2,2-dichloroethenyl)-2,2-dimethylcyclopropane-carboxylate.
• Permethrin has a molecular weight of 391.29 g/mole, and technical permethrin comprises from about 25 to 80% cis and about 20 to 75% trans isomers by weight.
• technical permethrin is suitable and it preferably has a minimum amount of the trans isomer of 45% by weight and a minimum amount of cis isomer of 35% by weight.
• the carrier is an alkyl glycol ether such as 2-(2-methoxybutoxy)ethanol or (most preferably) 2-(2-niethoxyethoxy)ethanol.
• insecticidal composition of the present invention comprising such a high percentage of the active ingredient, a pyrethroid, is effective against ectoparasites, while remaining non-irritating and non-toxic to the host.
• a composition of the invention having such a high concentration of active ingredient also allows for small, easily applied, and yet effective doses. No special expertise is required to apply the treatment, so animal owners may do so without the assistance of a veterinarian.
• inert ingredients can be added to the present composition, and can include up to 15% w/w of the total composition. They can include spreading agents, synergists, attractants, repellents, adhesion-promoters, surface-active agents, stabilisers, skin conditioners, perfumes, coat sheeners and colouring agents.
• Suitable spreading agents are liquids which distribute themselves particularly readily on the skin.
• Dipropylene glycol monomethylether is a particularly suitable spreading agent for inclusion within the compositions of the present invention.
• Isopropyl myristate is within the compositions of the present invention.
• Isopropyl myristate is another commonly used spreading agent.
• Attractants include phermones such as 2,6-dichlorophenol.
• Repellents include citronellol, diethyl toluimide, dimethyl phthalate, and the like.
• Adhesion promoters include carboxymethyl-cellulose, methylcellulose and other cellulose derivatives and starch derivatives, polyacrylates, alginates gelatin, gum arabic, polyvinylpyrrolidone, polyvinyl alcohol, copolymers of methyl vinyl ether and maleic anhydride, polyethylene glycols, paraffins, oils, waxes and hydrogenated castor oil, colloidal silicic acid or mixtures of the substances mentioned.
• compositions of the present invention do not normally contain surface active agents; however these may be included if desired.
• Surface-active agents include: 1. anionic surface active agents, such as sodium lauryl sulfate, fatty alcohol ethersulfates and monoethanolamine salts of mono-/di-alkylpolyglycol ether orthophosphoric acid esters, 2. cationic surface active agents, such as cetyltrimethyl-ammonium chloride, 3. amphophilic surface-active agents, such as disodium-N-lauryl-amino-diproprionate or lecithin, and 4.
• non-ionic surface active agents for example, polyoxyethylated castor oil, polyoxyethylated sorbitane monoleate, sorbitan monostearate, ethyl alcohol, glycerol monostearate, polyoxyethylene stearate and alkylphenol polyglycol ethers.
• stabilizers may also be used and include, for example, antioxidants, such as tocopherols, butyl-hydroxyanisole, butylhydroxytoluene and carbodiimides, (e.g. 2,2-6,6-tetraisopropyldiphenylcarbo-diimide) and scavengers such as epi-chlorohydrin.
• antioxidants such as tocopherols, butyl-hydroxyanisole, butylhydroxytoluene and carbodiimides, (e.g. 2,2-6,6-tetraisopropyldiphenylcarbo-diimide) and scavengers such as epi-chlorohydrin.
• Coloring agents include conventional dyes which are soluble in the carrier of the present invention, such as Sudan red or Oil Golden Yellow.
• a pyrethroid is heated to 65-80 degrees Centigrade until any crystals present are liquefied. The liquid is then mixed until uniform. A liquid carrier solvent is placed into a separate unheated vessel. The permethrin is then added to the vessel. The permethrin and carrier solvent are then mixed to uniformity. Additives may also be included in the vessel and mixed into the formulation.
• the additives comprise traditional pharmaceutical additives like skin conditioners, perfumes, coat sheeners, and spreading agents.
• permethrin is heated to about 65 degrees centigrade.
• the carrier 2-(2-methoxyethoxy)ethanol is placed in a clean tank and the permethrin added and mixed until uniform.
• the mixture may serve as a starting point for the formulation of topical preparations in other physical states.
• gelling agents may be added to create topical preparations in the form of gels and sols.
• Gases may be added to create topical preparations that can be delivered as aerosols.
• Other formulating agents may be added to the liquid mixture to create ointments and pastes.
• the insecticidal composition of the present invention is suitable for use on mammals, preferably domesticated companion animals such as dogs. Because it is so surprisingly non-toxic, it may be used on puppies as well as adult animals. It is also useful on a variety of domestic animals except that its use is not recommended for cats. It is also effective against a variety of parasites including ticks, fleas, keds, and mites.
• composition according to the present invention is particularly useful for horses and other large mammals because the doses required are much smaller as compared to the pyrethroid compositions of 50% w/w or lesser concentrations taught by the prior art.
• the insecticidal composition of this invention is useful for the control of insect and ascarine ectoparasites such as fleas, ticks, keds, and mites. Its most preferred use is for the control of ticks and fleas on dogs.
• the composition may be applied to the host animal by any conventional method for the localized application of compositions, for example by dropping a small volume of liquid composition on the animal's body.
• a highly concentrated composition is that only a small volume is necessary. While the necessary amount of the composition of the present invention needed to be applied for effective insecticidal activity depends upon the size of the animal and the precise concentration and delivery capabilities of the particular composition, a 1 ml volume of the preferred liquid composition has been found to be effective on dogs weighing less than 15 kg. A 1-2 milliliter volume of the preferred 65% w/w permethrin delivers 65-130 mg permethrin. On dogs larger than 15 kg, it has been found to be effective to apply 1 ml of 65% w/w permethrin composition between the shoulder blades in conjunction with another 1 ml at the tailhead.
• Treatment groups are defined in Table 1 entitled Experimental Design. TABLE 1 Experimental Design Group 1: Five dogs of various weights - untreated Group 2: Five dogs less than 15 kg (33 lbs) receiving 1 treatment between the shoulder blades. Group 3: Five dogs less than 15 kg (33 lbs) receiving treatment between the shoulder blades and at the tailhead. Group 4: Five dogs over 15 kg (33 lbs) receiving treatment between the shoulder blades and at the tailhead.
• Tick records indicate the location, sex, and stage of engorgement of each live, attached tick.
• the three treatments with the preferred composition were performed similarly throughout the study with percent control ranging from 70 to 89 on Day 1, 87 to 100 on Day 2, 92 to 100 on Day 3, 99 to 100 on Day 7, 97 to 100 on Day 14, 99 to 100 on Day 21, 93 to 95 on Day 28 and 63 to 89 on Day 35.
• Group 3 dogs weighing less than 15 kg (33 pounds) and treated with 1 cc. between the shoulder blades and 1 cc. at the tailhead
• Group 3 dogs weighing less than 15 kg (33 pounds) and treated with 1 cc. between the shoulder blades and 1 cc. at the tailhead
• Group 4 dogs weighing more than 15 kg (33 pounds) and treated with 1 cc. between the shoulder blades and 1 cc.
• Group 3 reached 89 and 100 percent control of Days 1 and 2 respectively whereas Group 2 reached 75 and 90 percent control and Group 4 reached 70 and 92 percent control on Days 1 and 2. Also, from Day 3 through Day 28, Group 3 was slightly higher (one to eight percentage points) in percent control than Group 2 and Group 4.
• Control of attached ticks on Day 3 was 70 percent in Group 2, 59 percent in Group 3 and 49 percent in Group 4.
• Groups 2 and 3 were similar in control (96-100 percent control) of post-treatment tick infestation through Day 21.
• Group 4 stayed at 90 percent control from Day 7 to 14 then increased to 98 percent control on Day 21.
• Days 28 and 35 the tick control figures for all three groups were falling slightly to 88-96 percent on Day 28 and 84 to 92 percent on Day 35.
• Tick counts and percent control are summarized in Table 4.
• TIME TREATMENT Group 1 None Group 2 less than 15 kg Shld. Group 3 less than 15 kg Shld./Tail Group 4 greater than 15 kg Shld./Tail Day -1 Ticks 131 99 98 114 Day 3 Ticks 63 19 26 32 % Control 70 59 49 Day 7 Ticks 110 4 0 11 % Control 96 100 90 Day 14 Ticks 119 1 1 12 % Control 99.1 99.1 90 Day 21 Ticks 183 1 2 4 % Control 99.5 99 98 Day 28 Ticks 203 24 9 16 % Control 88 96 92 Day 35 Ticks 193 16 23 30 % Control 92 88 84 (a. Shld. denotes treatment site was between the shoulder blades.) (b. Shld./Tail denotes that treatments were at two sites, one between the shoulders and the other at the
• Permethrin toxicity studies have been completed in numerous species, including rats, mice, rabbits, dogs, cats, cattle, poultry, swine and horses. This study documents the safety of the invention embodiment consisting of 65% w/w permethrin and 35% w/w 2(2-methoxyethoxy) ethanol on dogs.
• the two treatments consisted of 1 cc or 4cc of 65% w/w permethrin in 2-(2-methoxyethoxy)ethanol.
• Each dog was individually treated by administering the indicated amount of material (1cc or 4cc) to the shoulder blade area using a 1cc eyedropper.
• Dogs were observed for any signs of adverse reactions, including, but not limited to diarrhea, vomiting, salivation, excessive lacrimation, muscle fasciculations, hyperactivity, depression or anorexia. Dogs were noted as being normal if no signs were observable and the dog appeared similar to pretreatment observations and untreated dogs. Observations were noted immediately at the time of treatment, at two, four, six and eight hours after treatment and daily thereafter for four days. The treatment and observation process was repeated on days 7 through 11 and again on days 14-18, resulting in three treatments and three weeks of observations.
• adverse reactions including, but not limited to diarrhea, vomiting, salivation, excessive lacrimation, muscle fasciculations, hyperactivity, depression or anorexia. Dogs were noted as being normal if no signs were observable and the dog appeared similar to pretreatment observations and untreated dogs. Observations were noted immediately at the time of treatment, at two, four, six and eight hours after treatment and daily thereafter for four days. The treatment and observation process was repeated on days 7 through 11 and again on days 14-18, resulting in three treatments and

Landscapes

• Life Sciences & Earth Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Health & Medical Sciences (AREA)
• Dentistry (AREA)
• Zoology (AREA)
• Plant Pathology (AREA)
• Toxicology (AREA)
• Engineering & Computer Science (AREA)
• Agronomy & Crop Science (AREA)
• Wood Science & Technology (AREA)
• Pest Control & Pesticides (AREA)
• Environmental Sciences (AREA)
• Agricultural Chemicals And Associated Chemicals (AREA)
• Medicinal Preparation (AREA)
• Pretreatment Of Seeds And Plants (AREA)
• Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Applications Claiming Priority (3)

Publications (3)

Family

ID=23937628

Family Applications (1)

Country Status (14)

Cited By (3)

Families Citing this family (20)

Family Cites Families (12)

• 1991
  • 1991-02-28 BR BR919106124A patent/BR9106124A/pt not_active Application Discontinuation
  • 1991-02-28 ES ES91906319T patent/ES2103807T3/es not_active Expired - Lifetime
  • 1991-02-28 CA CA002077254A patent/CA2077254C/en not_active Expired - Lifetime
  • 1991-02-28 AU AU74795/91A patent/AU639549B2/en not_active Expired
  • 1991-02-28 DE DE69126776T patent/DE69126776T2/de not_active Expired - Lifetime
  • 1991-02-28 EP EP91906319A patent/EP0518989B1/en not_active Expired - Lifetime
  • 1991-02-28 DK DK91906319.8T patent/DK0518989T3/da active
  • 1991-02-28 JP JP3506114A patent/JP2978245B2/ja not_active Expired - Lifetime
  • 1991-02-28 WO PCT/US1991/001410 patent/WO1991013545A1/en active IP Right Grant
  • 1991-02-28 AT AT91906319T patent/ATE155007T1/de not_active IP Right Cessation
  • 1991-03-04 IE IE70891A patent/IE73280B1/en not_active IP Right Cessation
  • 1991-03-05 NZ NZ237313A patent/NZ237313A/en unknown
  • 1991-05-30 US US07/707,629 patent/US5236954A/en not_active Expired - Lifetime
• 1997
  • 1997-09-24 GR GR970402479T patent/GR3024840T3/el unknown

Also Published As

Similar Documents

Legal Events